- Home
- ELVA vs APLT Comparison
ELVA vs APLT Comparison
Compare ELVA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- APLT
- Stock Information
- Founded
- ELVA 1996
- APLT 2016
- Country
- ELVA Canada
- APLT United States
- Employees
- ELVA N/A
- APLT N/A
- Industry
- ELVA
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- APLT Health Care
- Exchange
- ELVA Nasdaq
- APLT Nasdaq
- Market Cap
- ELVA 91.8M
- APLT 80.3M
- IPO Year
- ELVA N/A
- APLT 2019
- Fundamental
- Price
- ELVA $2.39
- APLT $0.41
- Analyst Decision
- ELVA Strong Buy
- APLT Buy
- Analyst Count
- ELVA 5
- APLT 7
- Target Price
- ELVA $6.10
- APLT $6.10
- AVG Volume (30 Days)
- ELVA 67.5K
- APLT 1.5M
- Earning Date
- ELVA 05-12-2025
- APLT 05-08-2025
- Dividend Yield
- ELVA N/A
- APLT N/A
- EPS Growth
- ELVA N/A
- APLT N/A
- EPS
- ELVA N/A
- APLT N/A
- Revenue
- ELVA $43,693,000.00
- APLT N/A
- Revenue This Year
- ELVA $55.23
- APLT N/A
- Revenue Next Year
- ELVA $63.75
- APLT $2,426.33
- P/E Ratio
- ELVA N/A
- APLT N/A
- Revenue Growth
- ELVA N/A
- APLT N/A
- 52 Week Low
- ELVA $1.67
- APLT $0.40
- 52 Week High
- ELVA $3.58
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ELVA 50.41
- APLT 31.98
- Support Level
- ELVA $2.39
- APLT $0.40
- Resistance Level
- ELVA $2.70
- APLT $0.56
- Average True Range (ATR)
- ELVA 0.17
- APLT 0.05
- MACD
- ELVA -0.01
- APLT -0.01
- Stochastic Oscillator
- ELVA 32.26
- APLT 2.31
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.